keyword
MENU ▼
Read by QxMD icon Read
search

Omalizumab

keyword
https://www.readbyqxmd.com/read/28924988/benefit-from-reslizumab-treatment-in-a-patient-with-chronic-spontaneous-urticaria-and-cold-urticaria
#1
Marcus Maurer, Sabine Altrichter, Martin Metz, Torsten Zuberbier, Martin K Church, Karl-Christian Bergmann
Chronic urticaria (CU) is a group of common and debilitating conditions containing both chronic spontaneous urticaria (CSU) and chronic inducible urticarias (CIndU) including cold urticaria (ColdU) [1]. While antihistamines and omalizumab are effective treatments for both CSU and ColdU [2], many patients show insufficient response to either or both of these treatments [3], and additional and better therapies are needed [4]. This article is protected by copyright. All rights reserved.
September 19, 2017: Journal of the European Academy of Dermatology and Venereology: JEADV
https://www.readbyqxmd.com/read/28919788/innovative-treatments-for-severe-refractory-asthma-how-to-choose-the-right-option-for-the-right-patient
#2
REVIEW
Francesco Menzella, Carla Galeone, Francesca Bertolini, Claudia Castagnetti, Nicola Facciolongo
The increasing understanding of the molecular biology and the etiopathogenetic mechanisms of asthma helps in identification of numerous phenotypes and endotypes, particularly for severe refractory asthma. For a decade, the only available biologic therapy that met the unmet needs of a specific group of patients with severe uncontrolled allergic asthma has been omalizumab. Recently, new biologic therapies with different mechanisms of action and targets have been approved for marketing, such as mepolizumab. Other promising drugs will be available in the coming years, such as reslizumab, benralizumab, dupilumab and lebrikizumab...
2017: Journal of Asthma and Allergy
https://www.readbyqxmd.com/read/28918644/anti-ige-and-anti-il5-biologic-therapy-in-the-treatment-of-nasal-polyposis-a-systematic-review-and-meta-analysis
#3
Alexander Rivero, Jonathan Liang
OBJECTIVE: To determine the role of biologic therapy on sinonasal symptoms and objective outcomes in chronic rhinosinusitis with nasal polyposis (CRSwNP). METHODS: PubMed, OVID MEDLINE, and Cochrane Central were reviewed from 2000 to 2015. Inclusion criteria included English-language studies containing original data on biologic therapy in CRSwNP patients with reported outcome measures. Two investigators independently reviewed all manuscripts and performed quality assessment and quantitative meta-analysis using validated tools...
September 1, 2017: Annals of Otology, Rhinology, and Laryngology
https://www.readbyqxmd.com/read/28913986/chronic-spontaneous-urticaria-pathogenesis-and-treatment-considerations
#4
REVIEW
Allen P Kaplan
The treatment of chronic spontaneous urticaria begins with antihistamines; however, the dose required typically exceeds that recommended for allergic rhinitis. Second-generation, relatively non-sedating H₁-receptor blockers are typically employed up to 4 times a day. First-generation antihistamines, such as hydroxyzine or diphenhydramine (Atarax or Benadryl), were employed similarly in the past. Should high-dose antihistamines fail to control symptoms (at least 50%), omalizumab at 300 mg/month is the next step...
November 2017: Allergy, Asthma & Immunology Research
https://www.readbyqxmd.com/read/28913336/anti-interleukin-5-il-5-and-il-5ra-biological-drugs-efficacy-safety-and-future-perspectives-in-severe-eosinophilic-asthma
#5
REVIEW
Diego Bagnasco, Matteo Ferrando, Gilda Varricchi, Francesca Puggioni, Giovanni Passalacqua, Giorgio Walter Canonica
The definition of asthma has changed considerably in recent years, to the extent that asthma is no longer considered a single disease but a heterogeneous disorder that includes several phenotypes and, possibly, endotypes. A more detailed analysis of the immunological mechanisms underlying the pathogenesis of asthma shows interleukin 5 (IL-5) to be a crucial cytokine in several asthma phenotypes. In fact, IL-5 exerts selective action on eosinophils, which, in turn, sustain airway inflammation and worsen asthma symptoms and control...
2017: Frontiers in Medicine
https://www.readbyqxmd.com/read/28910970/antibody-therapy-for-the-management-of-severe-asthma-with-eosinophilic-inflammation
#6
Ken Ohta, Hiroyuki Nagase, Maho Suzukawa, Shin Ohta
One of the characteristic features of asthma is chronic airway inflammation typically with eosinophil infiltration. Most asthmatics can be treated successfully with conventional treatment appropriate for their severity, but in some severe cases, asthma cannot be well controlled even with thorough treatment and this condition is known as 'refractory asthma'. To overcome severe refractory asthma, a new therapeutic strategy with biologics has been developed based on the knowledge of molecular mechanisms of airway inflammation in asthma, induced by the condition of high Th2-type responses and activation of eosinophils as well as allergic reactions...
July 1, 2017: International Immunology
https://www.readbyqxmd.com/read/28888844/recurrence-of-chronic-urticaria-incidence-and-associated-factors
#7
Julie K Kim, Daniel Har, L Steven Brown, David A Khan
BACKGROUND: Chronic urticaria (CU) is urticaria that has been present continuously or intermittently for at least 6 weeks. Although the prevalence and characteristics of CU are well established, little is known about recurrent CU (RCU). OBJECTIVES: We sought to establish a definition, determine the frequency, and evaluate risk factors for RCU. METHODS: A retrospective chart review of adult patients with CU evaluated at the University of Texas Southwestern allergy and immunology clinic was performed...
September 6, 2017: Journal of Allergy and Clinical Immunology in Practice
https://www.readbyqxmd.com/read/28888244/new-and-anticipated-therapies-for-severe-asthma
#8
Stephen P Peters, William W Busse
Asthma is frequently undertreated, resulting in a relatively high prevalence of patients with uncontrolled disease, characterized by the presence of symptoms and risk of adverse outcomes. Patients with uncontrolled asthma have a higher risk of morbidity and mortality, underscoring the importance of identifying uncontrolled disease and modifying management plans to improve control. Several assessment tools exist to evaluate control with various cutoff points and measures, but these tools do not reliably correlate with physiological measures and should be considered a supplement to physiological tests...
September 2017: Journal of Allergy and Clinical Immunology in Practice
https://www.readbyqxmd.com/read/28870461/enhanced-plasmacytoid-dendritic-cell-antiviral-responses-after-omalizumab
#9
Michelle A Gill, Andrew H Liu, Agustin Calatroni, Rebecca Z Krouse, Baomei Shao, Allison Schiltz, James E Gern, Alkis Togias, William W Busse
BACKGROUND: Atopy and viral respiratory infections synergistically promote asthma exacerbations. IgE cross-linking inhibits critical viral-induced IFNα responses of plasmacytoid dendritic cells (pDCs), which can be deficient in allergic asthma. OBJECTIVE: To determine whether reducing IgE in vivo with omalizumab treatment increases pDC antiviral IFNα responses in inner city children with asthma. METHODS: PBMCs and pDCs isolated from children with exacerbation-prone asthma before and during omalizumab treatment were stimulated ex vivo with rhinovirus and influenza in the presence or absence of IgE cross-linking...
September 1, 2017: Journal of Allergy and Clinical Immunology
https://www.readbyqxmd.com/read/28870460/elevated-ige-levels-are-linked-to-faster-relapse-in-omalizumab-discontinued-chronic-spontaneous-urticaria-patients
#10
Ragip Ertas, Kemal Ozyurt, Emin Ozlu, Yilmaz Ulas, Atil Avci, Mustafa Atasoy, Tomasz Hawro, Marcus Maurer
No abstract text is available yet for this article.
September 1, 2017: Journal of Allergy and Clinical Immunology
https://www.readbyqxmd.com/read/28866106/elevated-baseline-d-dimer-plasma-levels-are-associated-with-a-prompt-response-to-omalizumab-in-patients-with-severe-csu
#11
Riccardo Asero, Angelo Valerio Marzano, Silvia Ferrucci, Massimo Cugno
No abstract text is available yet for this article.
August 30, 2017: Journal of Allergy and Clinical Immunology in Practice
https://www.readbyqxmd.com/read/28861213/idiopathic-non-histaminergic-acquired-angioedema-a-case-series-and-discussion-of-published-clinical-trials
#12
Martin Christian Bucher, Tatjana Petkovic, Arthur Helbling, Urs Christian Steiner
BACKGROUND: Idiopathic non-histaminergic acquired angioedema (InH-AAE) is a rare disease for which there are no available laboratory parameters to clearly define the disorder. Therapy is often difficult and various treatment options have been proposed. In this paper, we have evaluated the most effective therapies for InH-AAE on the basis of current literature and report the therapeutic effect of omalizumab in three patients with InH-AAE. METHODS: Literature was searched with a combination of MeSH/EMTREE terms and freetext search for angioedema and therapy/omalizumab in the databases Medline (Ovid), PubMed/Premedline, Embase, Cochrane library and Scopus with no time or language restrictions...
2017: Clinical and Translational Allergy
https://www.readbyqxmd.com/read/28861109/serum-free-ige-guided-dose-reduction-of-omalizumab-a-case-report
#13
Yasuhiro Gon, Reiko Ito, Shuichiro Maruoka, Kenji Mizumura, Yutaka Kozu, Hisato Hiranuma, Yuko Iida, Sotaro Shikano, Shu Hashimoto
BACKGROUND: Omalizumab is a human IgG1 antibody against IgE used as a therapy for sever asthmatic patients with asthma. According to the guidelines of the Global Initiative for Asthma, omalizumab is an add-on drug at treatment step 5 that is used for severe asthma patients who are allergic to perennial allergens. The effects of omalizumab for severe asthma therapy have been validated in multiple clinical studies. However, the long-term effects of omalizumab on IgE production and possibility of resetting of administration dose of omalizumab remain unknown...
2017: Allergy, Asthma, and Clinical Immunology
https://www.readbyqxmd.com/read/28859263/response-to-omalizumab-using-patient-enrichment-criteria-from-trials-of-novel-biologics-in-asthma
#14
Thomas B Casale, Bradley E Chipps, Karin Rosén, Benjamin Trzaskoma, Tmirah Haselkorn, Theodore A Omachi, Steven Greenberg, Nicola A Hanania
BACKGROUND: Recent efficacy studies of asthma biologics have included highly enriched patient populations. Using a similar approach, we examined factors that predict response to omalizumab to facilitate selection of patients most likely to derive the greatest clinical benefit from therapy. METHODS: Data from two phase III clinical trials of omalizumab in patients with allergic asthma were examined. Differences in rates of asthma exacerbations between omalizumab and placebo groups during the 16-week inhaled corticosteroid (ICS) dose-stable phase were evaluated with respect to baseline blood eosinophil counts (eosinophils <300/μL [low] vs ≥300/μL [high]) and baseline markers of asthma severity (emergency asthma treatment in prior year, asthma hospitalization in prior year, forced expiratory volume in 1 second [FEV1 ; FEV1 <65% vs ≥65% predicted], inhaled beclomethasone dipropionate dose [<600 vs ≥600 μg/day], long-acting beta-agonist [LABA] use [yes/no])...
August 31, 2017: Allergy
https://www.readbyqxmd.com/read/28859150/the-real-world-effect-of-omalizumab-add-on-therapy-for-patients-with-moderate-to-severe-allergic-asthma-the-asterix-observational-study
#15
Mohit Bhutani, William H Yang, Jacques Hébert, Frederica de Takacsy, Jean-Louis Stril
BACKGROUND: Omalizumab is a non-steroidal medication indicated for the treatment of poorly controlled moderate-to-severe allergic asthmatics. This observational study examines the "real world" effectiveness of omalizumab in this population. METHODS: This is a one year open-label observational study that compared clinical outcomes including total oral corticosteroid use, exacerbation history, measures of quality of life and inflammation in patients with moderate-to-severe allergic asthma, who were prescribed omalizumab as part of their treatment with the year prior to therapy...
2017: PloS One
https://www.readbyqxmd.com/read/28838976/clinical-and-biological-characteristics-of-the-french-cobra-cohort-of-adult-subjects-with-asthma
#16
Marina Pretolani, David Soussan, Isabelle Poirier, Gabriel Thabut, Michel Aubier
The COhort of BRonchial obstruction and Asthma (COBRA) is a longitudinal cohort that involves 12 French academic institutions. DNA, serum samples and clinical data are collected at entry and every 6 months thereafter.Of 1080 patients with asthma recruited between 2007 and 2015, 401 had mild/moderate and 613 had severe asthma. In cross-sectional analyses, compared with patients with milder disease, patients with severe asthma had more symptoms, exacerbations, hospitalisations and visits to the emergency department during the preceding 12 months, higher numbers of blood eosinophils, and more comorbidities...
August 2017: European Respiratory Journal: Official Journal of the European Society for Clinical Respiratory Physiology
https://www.readbyqxmd.com/read/28827590/omalizumab-efficacy-in-cases-of-chronic-spontaneous-urticaria-is-not-explained-by-the-inhibition-of-sera-activity-in-effector-cells
#17
Eva Serrano-Candelas, Rubén Martínez-Aranguren, Olga Vega, Gabriel Gastaminza, Joan Bartra, Maria Teresa Audicana, Jorge M Núñez-Córdoba, Jaime Algorta, Antonio Valero, Margarita Martin, Marta Ferrer
Omalizumab (OmAb) is a humanized anti-IgE antibody approved for the treatment of chronic spontaneous urticaria (CSU). OmAb's mechanism of action is known to include actions on free IgE and on pre-bound IgE. However, OmAb is equally and rapidly effective against autoimmune and non-autoimmune urticaria where IgE involvement is not clear, suggesting the involvement of additional mechanisms of action. In this study, we sought to investigate the ability of OmAb to inhibit mast cell and basophil degranulation induced by sera from CSU patients...
August 21, 2017: Scientific Reports
https://www.readbyqxmd.com/read/28825866/immunotherapy-for-cow-s-milk-allergy
#18
Shoichiro Taniuchi, Masaya Takahashi, Kazukiko Soejima, Yasuko Hatano, Hirotaka Minami
Oral immunotherapy (OIT) is used regularly for young children with cow's milk (CM) allergy and has been shown to be effective in several studies. However, adverse events occur frequently during OIT. Furthermore, there are only five randomized controlled trial studies of CM-OIT and these are low-powered single center trials. Therefore, evidence levels are also low and sometimes frequent and severe allergic events occur during the OIT. Furthermore, there are no standardized protocols in pediatric allergy guidelines from several countries and studies with long-term follow-up observations and clinical tolerance defined as sustained unresponsiveness are rare...
August 21, 2017: Human Vaccines & Immunotherapeutics
https://www.readbyqxmd.com/read/28815189/a-case-of-pulmonary-vein-thrombosis-associated-with-treatment-of-omalizumab
#19
Sandhya Narukonda, Nagadarshini Ramagiri Vinod, Medha Joshi
Pulmonary vein thrombosis (PVT) is a challenging diagnosis and has been described in association with or as a complication of pulmonary tumors, lung surgeries, atrial myxoma, and after radiofrequency catheter ablation for atrial fibrillation. There are not many reported cases of PVT associated with medication use. We present a case of a 53-year-old male with a history of severe persistent asthma on omalizumab, who presented with shortness of breath and was found to have PVT on computed tomography scan of the chest...
July 2017: Journal of Investigative Medicine High Impact Case Reports
https://www.readbyqxmd.com/read/28815007/appropriate-selection-for-omalizumab-treatment-in-patients-with-severe-asthma
#20
Leo Nygaard, Daniel Pilsgaard Henriksen, Hanne Madsen, Jesper Rømhild Davidsen
Background: Omalizumab improves asthma control in patients with uncontrolled severe allergic asthma; however, appropriate patient selection is crucial. Information in this field is sparse. Objective: We aimed to estimate whether potential omalizumab candidates were appropriately selected according to guidelines, and the clinical effect of omalizumab treatment over time. Design: We performed a retrospective observational study on adult patients with asthma treated with omalizumab during 2006-2015 at the Department of Respiratory Medicine at Odense University Hospital (OUH), Denmark...
2017: European Clinical Respiratory Journal
keyword
keyword
7812
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"